Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 13/20 | 0.72 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.72 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.72 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.66 |
| ▸ | TMPRSS4 | Q9NRS4 | 7/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | IKBKB | O14920 | 1/20 | 0.63 |
| ▸ | CHUK | O15111 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 1/20 | 0.63 |
| ▸ | FLT3 | P36888 | 1/20 | 0.63 |
| ▸ | MYLK | Q15746 | 1/20 | 0.63 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9322590 | 0.89 | P2RX1 (0.73) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL12368137 | 0.89 | NPC1 (0.68) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL127962 | 0.84 | P2RX1 (1.00) | P2RX1P2RX7P2RX4P2RX3TMPRSS4 | |
| SCHEMBL5426499 | 0.81 | KMT2A (0.84) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL130439 | 0.81 | P2RX1 (0.81) | P2RX1P2RX7P2RX4TMPRSS4MEN1 | |
| SCHEMBL4928355 | 0.81 | P2RX1 (0.76) | P2RX1P2RX7P2RX4P2RX3TMPRSS4 | |
| SCHEMBL10910605 | 0.80 | TRPV1 (0.67) | TMPRSS4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL30084384 | 0.80 | MEN1 (0.77) | TMPRSS4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL29890853 | 0.80 | MEN1 (0.77) | TMPRSS4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL57970 | 0.80 | MEN1 (0.77) | TMPRSS4MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | claimed |
| US-9266872-B2 | 2-hydroxyarylamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2016-02-23 | — | — | US | disclosed |
| EP-1512397-B1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2014-10-08 | — | — | EP | disclosed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | disclosed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | disclosed |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | disclosed |
| WO-2013058613-A2 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | 한국생명공학연구원 (KR) | 2013-04-25 | — | — | WO | disclosed |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7626042-B2 | O-substituted hydroxyaryl derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-0780363-B1 | Bisazo-benzofuran compounds, their use as charge carrier generating compounds | SHARP KK (JP) | 2001-09-26 | — | — | EP | disclosed |
| US-5853930-A | Electrophotographic photoconductors using bisazo compounds | SHARP KABUSHIKI KAISHA (JP) | 1998-12-29 | — | — | US | disclosed |
| EP-0780363-A1 | Bisazo-benzofuran compounds, their use as charge carrier generating compounds and intermediates for their preparation | SHARP KABUSHIKI KAISHA (JP) | 1997-06-25 | — | — | EP | disclosed |
| US-4913997-A | PHOTOSENSITIVE LAYER CONTAINING AZO PIGMENTS, HIGH DIRABILITY, MOISTURE RESISTANCE, THERMAL STABILITY | MITSUBISHI PAPER MILLS LIMITED (JP) | 1990-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | IL1A, TNF, NFKBIA | P2RX1 2507/4885P2RX7 2251/4885P2RX4 3900/4885 |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | RELA, NFKBIA, NFE2 | P2RX1 3644/4885P2RX7 3286/4885P2RX4 4206/4885 |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | TMPRSS2, TMPRSS4, PRSS2 | P2RX1 4273/4885P2RX7 4289/4885P2RX4 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.